Trial Profile

A 52-Week, Multinational, Multi-Centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Detemir and NPH Insulin in Children and Adolescents 2-16 years with Type 1 Diabetes on a Basal-Bolus Regimen with Insulin Aspart as Bolus Insulin

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin detemir (Primary) ; Insulin aspart; Insulin suspension isophane
Indications Type 1 diabetes mellitus
Focus Registrational; Therapeutic Use
Sponsors Novo Nordisk

24 Oct 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
29 Jun 2012 Official title amended as reported by European Clinical Trials Database.(Parent trial: EudraCT2006-000051-18).
30 Sep 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com